UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 120.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,849 shares of the company's stock after acquiring an additional 9,202 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.06% of GeneDx worth $1,295,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its stake in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after acquiring an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx in the fourth quarter worth $28,000. Lazard Asset Management LLC acquired a new stake in shares of GeneDx in the fourth quarter worth $35,000. Comerica Bank acquired a new stake in shares of GeneDx in the fourth quarter worth $50,000. Finally, Quarry LP acquired a new stake in shares of GeneDx in the fourth quarter worth $78,000. Institutional investors own 61.72% of the company's stock.
Insider Transactions at GeneDx
In other GeneDx news, Director Keith A. Meister purchased 100,000 shares of the company's stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $56.01 per share, for a total transaction of $5,601,000.00. Following the purchase, the director now owns 3,008,629 shares in the company, valued at approximately $168,513,310.29. The trade was a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Kevin Feeley sold 370 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $71.26, for a total value of $26,366.20. Following the completion of the sale, the chief financial officer now owns 4,105 shares in the company, valued at approximately $292,522.30. This trade represents a 8.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 134,627 shares of company stock worth $12,590,999 in the last 90 days. Corporate insiders own 29.60% of the company's stock.
GeneDx Trading Down 2.7%
Shares of WGS stock traded down $1.80 on Friday, reaching $64.57. The company had a trading volume of 491,417 shares, compared to its average volume of 783,249. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average of $78.86 and a 200-day moving average of $81.96. GeneDx Holdings Corp. has a 12 month low of $24.91 and a 12 month high of $117.75. The stock has a market cap of $1.84 billion, a PE ratio of -32.94 and a beta of 1.94.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.17. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $87.12 million during the quarter, compared to analyst estimates of $79.90 million. On average, equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages recently commented on WGS. TD Securities reduced their target price on GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Wells Fargo & Company cut their price target on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Guggenheim began coverage on GeneDx in a report on Thursday, May 15th. They issued a "buy" rating and a $88.00 price target for the company. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Finally, Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $86.75.
Read Our Latest Report on WGS
GeneDx Company Profile
(
Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Further Reading
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
